Indegene Limited is a “digital-first” commercialization company focused exclusively on the global life sciences industry. Their solutions enable biopharmaceutical, emerging biotech and medical devices companies develop products, launch them in the market, and drive sales through their life cycle in a more effective, efficient manner. They achieve this by combining over two decades of healthcare domain expertise and fit-for-purpose technology. The portfolio of solutions cover all aspects of commercial, medical, regulatory and R&D operations of life sciences companies.
Strengths And Risks + Domain expertise: Indegene has deep understanding of the healthcare domain that enables them to efficiently modernize and digitize the key functions involved in the life sciences commercialization process. This requires in-depth domain expertise of the journey of a drug or medical device from the research lab to the market to be able to organize and analyze scientific and clinical data, navigate the regulatory landscape and the ethical guidelines.
+ Robust digital capabilities : Over the years, they have developed a suite of proprietary tools and platforms, including applications that automate and create AI-based efficiencies using AI, ML, NLP and advanced analytics capabilities that are core components of their solutions.
+ Long-standing client relationships: Indegene has long-standing relationships with marquee biopharmaceutical companies including 19 of the 20 largest biopharmaceutical companies in the world. Additionally, they also serve clients in the mid-sized pharma, emerging biotech, and medical devices industries.
+ Global delivery model: We cater to their clients from six operation hubs and 16 offices located across North America, Europe and Asia, through two delivery models, namely enterprise-wide technology-enabled COEs and digital Omnichannel Activation solutions.
- Regulatory requirements: Company is required to adhere to regulatory requirements governing the promotion, sales, and marketing of life sciences products. Such laws limit the kinds of financial arrangements that life sciences companies may have with healthcare professionals, patients and payors. They also impose additional administrative and compliance burdens, such as filing or reporting requirements.
- Highly Competitive Industry: The life sciences operations industry is highly competitive, and it is difficult to predict its future prospects.
- Regional Concentration: A significant portion of their business is attributable to certain large clients located in North America and Europe. Any deterioration of their financial condition or prospects or any adverse changes in economic and political conditions in these regions may have an adverse impact on business.
FAQs What is the Indegene Limited IPO? +
When will the IPO open? +
What is the lot size of the IPO? +
How to apply for an IPO? +
When will the IPO be allotted? +
When is the IPO listing date? +